Eli Lilly (LLY) Director Reports 2,003.492 Deferred Shares on Form 4
Rhea-AI Filing Summary
Mary Lynne Hedley, a director of Eli Lilly & Co. (LLY), reported an internal acquisition of common stock on 09/15/2025. The filing shows 2,003.492 shares were acquired and recorded as deferred stock units under the Lilly Directors' Deferral Plan, to be settled in shares following the reporting person's separation from service. The report lists a per-share amount of $748.19 associated with the transaction. The reporting person disclaims beneficial ownership except to the extent of a pecuniary interest, noting the shares are held by a trust. The Form 4 was signed on behalf of Hedley by Jonathan Groff on 09/17/2025.
Positive
- Director equity alignment: 2,003.492 shares were deferred under the Lilly Directors' Deferral Plan, tying compensation to company stock
- Clear disclosure: Filing specifies deferral mechanics and trust holding, supporting transparency
Negative
- None.
Insights
TL;DR: Director deferred compensation into 2,003.492 shares, indicating standard director equity deferral; not a market trade signal.
The filing documents a non-derivative acquisition through the companys directors deferral plan rather than an open-market purchase. The transaction date is 09/15/2025 and the record shows 2,003.492 common shares acquired as deferred units, with settlement tied to separation from service. For investors, such filings generally reflect compensation mechanics and long-term alignment rather than active market accumulation.
TL;DR: Routine director deferral reported; disclosure includes trust-held shares and a pecuniary-interest disclaimer.
The report clearly states the shares were deferred in lieu of cash under the Lilly Directors' Deferral Plan and will be settled in shares after the reporting person's separation. The reporting person also disclaims beneficial ownership except for pecuniary interest and indicates the shares are held by a trust. This presentation aligns with typical governance disclosures for director compensation deferrals.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 13.254 | $748.19 | $10K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. The reporting person disclaims beneficial ownership of the reported securities except to the extent of the reporting person's pecuniary interest therein, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.